TL;DR
This study investigates how ovarian cancer cells change their identity (epithelial to mesenchymal, and back) through epigenetic modifications. They found that the transcription factor GRHL2 plays a key role in maintaining epithelial characteristics by influencing DNA methylation and histone modifications, and that targeting these epigenetic mechanisms can influence this plasticity.
What Problem Does This Paper Address?
Cancer cells can switch between different states, a phenomenon called epithelial-mesenchymal transition (EMT) and its reverse (MET). This plasticity is crucial for cancer spread and drug resistance, but the underlying epigenetic mechanisms, especially during the intermediate "hybrid" states, are not fully understood. Specifically, how genes that promote an epithelial state are epigenetically controlled during these transitions, and what role transcription factors like GRHL2 play in this process, remains an open question.
Methods
The researchers employed a multi-omics approach:
- DNA Methylation Analysis: Using the Illumina HumanMethylation450K array to assess genome-wide DNA methylation patterns across 30 ovarian cancer cell lines with varying EMT states.
- ChIP-sequencing (ChIP-seq): To profile five key histone marks (H3K4me1, H3K4me3, H3K27Ac, H3K27me3, and H3K9me3) associated with gene activation and repression.
- Transcriptome Profiling (RNA-seq): To measure gene expression levels.
- GRHL2 Knockdown and Overexpression Models: Using shRNA to reduce GRHL2 levels and a Tet-On system to induce GRHL2 expression in specific cell lines.
- Epigenetic Drug Treatments: Employing 5-azacitidine (a DNA methylation inhibitor), GSK126 (an EZH2 inhibitor), and mocetinostat (an HDAC inhibitor) to probe the effects of epigenetic modulation.
- ChromHMM Analysis: To predict combinatorial chromatin states based on histone mark patterns.
- Motif Analysis: To identify transcription factor binding motifs enriched at differentially methylated regions.
Datasets
- Ovarian Cancer Cell Lines: A panel of 30 ovarian cancer cell lines with established EMT scores.
- GRHL2 Knockdown Model: OVCA429 cells with GRHL2 knocked down.
- GRHL2 Overexpression Models: OVCA429 shGRHL2 cells and HEYA8 cells engineered to overexpress GRHL2.
- Public ChIP-seq Databases: Used for enrichment analysis (ReMap2018).
Key Insights and Ideas
- Epithelial Genes are Epigenetically Vulnerable: The study highlights that genes promoting an epithelial state are more susceptible to epigenetic regulation (DNA methylation and histone modifications) during EMT compared to mesenchymal genes.
- GRHL2 as an Epigenetic Maestro: GRHL2, an EMT suppressor, appears to actively maintain epithelial gene expression by influencing DNA methylation and histone marks, particularly at its own binding sites and those of epithelial genes.
- GRHL2 Knockdown Mimics EMT: Reducing GRHL2 levels leads to epigenetic changes (gain of DNA methylation, shift towards repressive histone marks) that mirror the epigenetic landscape of cells undergoing progressive EMT.
- Intermediate States are Key: The epigenetic control of epithelial genes is most evident during intermediate EMT/MET phases, suggesting these states are actively regulated rather than just passive transitions.
- Combinatorial Epigenetic Control: The interplay between DNA methylation, various histone modifications, and transcription factors like GRHL2 is crucial for regulating epithelial gene expression during EMT/MET.
Key Results
- Differentially Methylated CpGs (DMCs): Identified thousands of DMCs correlated with EMT, with a higher proportion of EMT+ DMCs (positively correlated with EMT) found near promoters of epithelial genes.
- GRHL2 Knockdown Effects: GRHL2 knockdown led to a significant gain in CpG methylation at epithelial genes and GRHL2 binding sites, along with a shift from active to repressive histone marks (e.g., reduced H3K4me3/H3K27ac, increased H3K27me3).
- MET Induction: GRHL2 overexpression, particularly when combined with epigenetic drugs (5-azacitidine, GSK126, mocetinostat), could induce MET (restore epithelial characteristics) in cells with intermediate EMT states, but was less effective in fully mesenchymal cells.
- Drug Synergy: Epigenetic inhibitors (EZH2 and HDAC inhibitors) enhanced GRHL2-mediated MET, suggesting a synergistic effect in reactivating epithelial genes.
- TF Binding and Epigenetics: Motif analysis revealed that GRHL2 binding sites were enriched for EMT+ DMCs, supporting its role in regulating methylation of epithelial genes.
Limitations and Future Work
- Drug Specificity: The authors acknowledge that current epigenetic-modifying drugs have limitations in specificity and can cause cellular toxicity.
- Complex Regulation: The precise mechanisms by which GRHL2 interacts with specific DNMTs, TET enzymes, and other epigenetic modifiers (like HDACs and PRC2) require further investigation.
- Three-Dimensional Chromatin Structure: The role of long-range DNA interactions and chromatin looping in regulating epithelial genes, especially in GRHL2-null cells, needs further exploration.
- Single-Cell Analysis: The authors suggest that future studies could benefit from single-cell analysis to better understand the heterogeneity of EMT plasticity within cell populations.
- Novel Targeted Approaches: The need for novel targeted epigenome editing tools (e.g., CRISPR/Cas9) is highlighted for more precise functional validation of locus-specific epigenetic modifications.
Summary updated